{"id":312918,"date":"2010-02-12T12:15:59","date_gmt":"2010-02-12T17:15:59","guid":{"rendered":"http:\/\/blogs.wsj.com\/health\/2010\/02\/12\/indian-ceo-us-would-grant-a-patent-to-a-piece-of-toilet-paper\/"},"modified":"2010-02-12T12:15:59","modified_gmt":"2010-02-12T17:15:59","slug":"indian-ceo-%e2%80%98u-s-would-grant-a-patent-to-a-piece-of-toilet-paper%e2%80%99","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/312918","title":{"rendered":"Indian CEO: \u2018U.S. Would Grant a Patent to a Piece of Toilet Paper\u2019"},"content":{"rendered":"

India has become a hot market for multinational drug companies since it revised its patent laws to give more protection to brand-name medicine. But to hear the branded makers tell it, the patent welcome mat has some holes in it, a WSJ report<\/a> recounts this morning.<\/p>\n

\"patent\"The drug makers point to three top-selling medicines that have failed in their efforts to win protection either through India\u0092s patent office or the country\u0092s court system. Most recently, Delhi\u0092s High Court Tuesday dismissed an appeal by Bayer to block copies of its cancer medicine Nexavar, calling the appeal “a speculative foray,” the article said.<\/p>\n

Last year, the patent office decided<\/a> that Novartis’s patent application for Glivec (sold in the U.S. as Gleevec) didn’t demonstrate improved efficacy over an earlier version of the cancer treatment. Meanwhile, a patent was approved for Roche\u0092s cancer drug Tarceva, but the company has lost bids to block sales of copycat versions of the drug.<\/p>\n

The rub is that 2005 changes that expanded patent protections also set higher standards than are used in the U.S. or Europe for approving patents. “The U.S. would grant a patent to a piece of toilet paper,” the CEO of Indian generics maker Cipla told the WSJ. “Just because the U.S. granted a patent, doesn’t mean it should be valid.”<\/p>\n

Multinational pharma companies have been saying for a while that this makes doing business in India tougher. As far back as 2007, Novartis said it was scrapping plans<\/a> to invest hundreds of million of R&D dollars in India in the wake of its Glivec setbacks.<\/p>\n

A Roche spokesman told the WSJ this week that the failure of its efforts to protect Tarceva means “any research-based company will need to consider carefully what this ruling means for future investments in this country.”<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

\n<\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a>\n<\/div>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

India has become a hot market for multinational drug companies since it revised its patent laws to give more protection to brand-name medicine. But to hear the branded makers tell it, the patent welcome mat has some holes in it, a WSJ report recounts this morning. The drug makers point to three top-selling medicines that […]<\/p>\n","protected":false},"author":792,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-312918","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/312918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/792"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=312918"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/312918\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=312918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=312918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=312918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}